Big Market Research added a report titled, “Viral Vector and Plasmid DNA Manufacturing Market By Product (Viral Vectors, Plasmid DNA, And Non-Viral Vectors) And Application (Cancer, Inherited Disorders, Viral Infections, And Others) - Global Opportunity Analysis And Industry Forecast, 2017-2023”, which says that the market was valued at $261 million in 2016 and is likely to reach $1,090 million by 2023, growing at a CAGR of 22.6% from 2017 to 2023. The study explains the current market scenario and the growth prospects of the overall market.
The information provided in the report is a result of an extensive primary and secondary research analysis with analyst tools & models. It provides a bird’s eye view on the entire market with the help of market size and forecast, research methodology, Porter’s five forces analysis, drivers, restraints, and opportunities, market segmentation, key market trends, market players, and more.
The viral vector and plasmid DNA manufacturing market report analyze the market segmentation based on product type, application, and geography. By product type, the market is classified into plasmid DNA, viral vectors, and non-viral vectors. Based on application, the report divides the market into cancer, inherited disorders, viral infections, and others. Based on geography, the report segments the market into North America, Europe, Asia-Pacific, and LAMEA. In North America, the study analyzes the market across the U.S., Canada, and Mexico. In Europe, the study covers the regions such as Germany, France, UK, Italy, Spain, and the other parts of Europe. In Asia-Pacific, the market analysis has been covered for Japan, China, Australia, India, South Korea, Taiwan, and the rest of Asia-Pacific. The market study in the LAMEA region covers Brazil, Saudi Arabia, South Africa, and the rest of LAMEA.
The report includes a mention of the drivers, restraints, and opportunities impacting the viral vector and plasmid DNA manufacturing market. The rise in funding for R&D activities pertaining to gene therapy, the growing occurrence of cancer, viral infection, and genetic disorders, and the rising awareness of gene therapy are contributing to the market growth. Furthermore, the growing demand for synthetic genes and the untapped potential for emerging markets provide opportunities for market growth. Nevertheless, the high cost associated with gene therapies and the risk of mutagenesis and other impediments in gene therapy are acting as obstacles to the growth of the market.
The report provides a competitive analysis and profiles of the major players operating in the viral vector and plasmid DNA manufacturing market. They include Kaneka Eurogentec S.A., FinVector, Brammer Bio, Cell and Gene Therapy Catapult, FUJIFILM Diosynth Biotechnologies, Sanofi, Spark Therapeutics, Cobra Biologics, UniQure, and MassBiologics. Other players in the value chain analysis include 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Ltd., and Thermo Fisher Scientific, Inc.
The report provides a thorough analysis of the global viral vector and plasmid DNA manufacturing market. It serves as a useful tool for market players, new entrants, and investors. It helps them gain insights into the overall market and plan informed business strategies to gain fruitful outcomes. The report presents a quantitative analysis of the market for the period 2017-2023 to allow stakeholders to capitalize on the prevailing market opportunities. An analysis of the market based on its segmentation assists in identifying the trends in the industry. Information about the companies helps players better understand the competitor and gain more insights to better position their business. Besides the general overview, the report covers the business segments and product portfolio, and the strategic moves and developments of each player. The report also includes a country wise analysis of the market to identify the lucrative investment pockets.